article/article.tpl

An e-learning programme about the risk and management of QTc-prolongation in community pharmacies significantly improves pharmacists’ (long- term) knowledge

Eline Vandael, Els Verstuyft, Chantal Leirs, Veerle Foulon

Abstract

Objective: To develop an e-learning programme about the risk of QTc-prolongation and to evaluate its impact on knowledge.

Methods: An e-learning programme, covering all aspects of QTc-prolongation, was developed and implemented in a Flemish pharmacy network. Pre-post knowledge tests and a satisfaction questionnaire were used to evaluate the impact.

Results: Overall, 166 pharmacists completed the e-learning, pre-post knowledge tests and satisfaction questionnaire. The median score on the knowledge test before the e-learning was 9/19 (IQR 6-11); this increased to 16/19 (IQR 15-18; p<0.001) immediately after the e-learning, and 12/19 (IQR 10-14) ten months later. The median satisfaction score was 9/10 (IQR 8-10). Most pharmacists indicated that they were more confident about their knowledge after following the training, and that this knowledge can be used in practice.

Conclusions: An e-learning about the risk of QTc-prolongation yielded high satisfaction scores among pharmacists. The training led to a significant increase in (long-term) knowledge. 


Keywords

Community Pharmacies, e-Learning, QTc-Prolongation, Risk Management


Full Text:

PDF

References

Acco. (2016). Sofia: online learn platform. Available at: https://www.sofialearn.com. Accessed 8th April, 2016.

Al-Khatib, S.M., Allen LaPointe, N.M., Kramer, J.M., Chen, A.Y., Hammill, B.G., Delong, L. & Califf, R.M. (2005). A survey of health care practitioners' knowledge of the QT interval. Journal of General Internal Medicine, 20, 392-6.

American Society of Health-System Pharmacists [ASHP]. (2013). Clinically Important Drug-Drug Interactions and Clinical Decision Support On Demand Webinar. Available at: http://elearning.ashp.org/products/ 1436/clinically- important-drug-drug-interactions-and-clinical-decision- support-on-demand-webinar. Accessed 16th May, 2016.

Ames, D., Camm, J., Cook, P., Falkai, P., Gury, C., Hurley, R., Johnson, G., Piepho, R. & Vieweg V. (2002). Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. Encephale, 28, 552-62.

BAPCOC: Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. (2012). Available at:http://www.pubmed.be/832250_BW_NL_01_84_IC. pdf. Accessed 8th April, 2016.

Beach, S.R., Celano, C.M., Noseworthy, P.A., Januzzi, J.L. & Huffman, J.C. (2013). QTc Prolongation, Torsades de Pointes, and Psychotropic Medications. Psychosomatics, 54, 1-13.

Cain, J. & Fox, B.I. (2009). Web 2.0 and pharmacy education. American Journal of Pharmaceutical Education, 73, 120.

Choo, W.K., Turpie, D., Milne, K., Davidson, L., Elofuke, P., Whitfield, J. & Broadhurst, P. (2014) Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications. Cardiovascular Therapeutics, 32, 209-13.

CredibleMeds. (2016). Woosley, R.L., Romero, K.A. QTdrugs List, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Available at: http://www.credible meds.org. Accessed 2nd October, 2016.

Drew, B.J., Ackerman, M.J., Funk, M., Gibler, W.B., Kligfield, P., Menon, V., Philippides, G.J., Roden, D.M. & Zareba, W. (2010). Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology, 55, 934-47.

Famhp: Federal Agency for Medicines and Health Products. (2016) Available at: http://www.fagg-afmps.be/ en. Accessed 8th April, 2016.

Fanoe, S., Kristensen, D., Fink-Jensen, A., Jensen, H.K., Toft, E., Nielsen, J., Videbech, P., Pehrson, S. & Bundgaard, H. (2014). Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal, 35, 1306-15.

Fongemie, J.M., Al-Qadheeb, N.S., Estes, N.A., Roberts, R.J., Temtanakitpaisan, Y., Ruthazer, R. & Devlin, J.W. (2013). Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation. Pharmacotherapy, 33, 589-97.

Haugaa, K.H., Bos, J.M., Tarrell, R.F., Morlan, B.W., Caraballo, P.J. & Ackerman, M.J. (2013). Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clinic Proceedings, 88, 315-25.

Heathbase. (2015-2016). Commentaren Medicatiebewaking, edition 2015/2016.

International Conference on Harmonisation. (2005). Guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice Federal Register, 70, 61133-4.

Isbister, G.K. & Page, C.B. (2013). Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. British Journal of Clinical Pharmacologg, 76, 48-57.

Kirkpatrick, D. (1996). Great ideas revisited: revisiting Kirkpatrick's four-level model. Training & Development, 50, 54-60.

Legris, M.E., Seguin, N.C., Desforges, K., Sauve, P., Lord, A., Bell, R., Berbiche, D., Desrochers, J.F., Lemieux, J.P., Morin-Belanger, C., et al. (2011) Pharmacist Web-based training program on medication use in chronic kidney disease patients: impact on knowledge, skills, and satisfaction. Journal of Continuing Education in Health Professions, 3, 140-50.

Maggio, L.A., Cate, O.T., Irby, D.M. & O'Brien, B.C. (2015). Designing evidence-based medicine training to optimize the transfer of skills from the classroom to clinical practice: applying the four component instructional design model. Academic Medicine, 90, 1457-61.

Marzuillo, P., Benettoni, A., Germani, C., Ferrara, G., D'Agata, B. & Barbi, E. (2014). Acquired long QT syndrome: a focus for the general pediatrician. Pediatric Emergency Care, 30, 257-61.

Morita, H., Wu, J. & Zipes, D.P. (2008). The QT syndromes: long and short. Lancet, 372, 750-63.

Nachimuthu, S., Assar, M.D. & Schussler, J.M. (2012). Drug-induced QT interval prolongation: mechanisms and clinical management. Therapeutic Advances in Drug Safety, 3, 241-53.

NIHDI [National Institute for Health and Disability Insurance]. (2016). Medisch-farmaceutisch overleg - Lokaal project (online). Available at: http://www.inami.fgov.be/nl/themas/zorgkwaliteit/geneesmiddelen/medisch - farmaceutisch-overleg/Paginas/lokaal-project.aspx#. Vwe1Npy LSM8. Accessed 8th April, 2016.

Pickham, D. (2013). Understanding and documenting QT intervals. Critical Care Nurse, 33, 73-5.

Roden, D.M. (2004). Drug-induced prolongation of the QT interval. The New England Journal of Medicine, 350, 1013-22.

Ruiz, J.G., Mintzer, M.J., Leipzig, R.M. (2006). The impact of E-learning in medical education. Academic Medicine, 81, 207-12.

Salter, S.M., Karia, A., Sanfilippo, F.M. & Clifford, R.M. (2014). Effectiveness of E-learning in pharmacy education. American Journal of Pharmaceutical Education, 78, 83.

Samenwerkingsverband APB-OPHACO. (2016). Permanente vorming van apothekers: E-learning rond QT- verlenging. Available at: http://vorming apothekers.be/lijst- erkende-vormingsactiviteiten/16-021- 001/. Accessed 8th April, 2016.

Sarganas, G., Garbe, E., Klimpel, A., Hering, R.C., Bronder, E. & Haverkamp, W. (2014). Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace, 16, 101-8.

Tay, K.Y., Ewald, M.B. & Bourgeois, F.T. (2014). Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiology Drug Safety, 23, 9-17.

Tisdale, J.E., Jaynes, H.A., Kingery, J.R., Mourad, N.A., Trujillo, T.N., Overholser, B.R. & Kovacs, R.J. (2013). Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation: Cardiovascular Quality and Outcomes, 6, 479-87.

UPB-AVB, Huis voor gezondheid, RML-B. (2013). Handleiding voor een kwalitatief overleg tussen apotheker en huisarts.

U.S. Department of Health and Human Services. (2005). Guidance for Industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non- antiarrhythmic drugs.

Vandael, E., Marynissen, T., Reyntens, J., Spriet, I., Vandenberghe, J., Willems, R. & Foulon, V. (2014). Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. International Journal of Clinical Pharmacy, 36, 757-765.

Vandael, E., Vandenberk, B., Vandenberghe, J., Spriet, I., Willems, R. & Foulon, V. (2016). Risk management of QTc-prolongation in patients receiving haloperidol: an observational study in a university hospital in Belgium. International Journal of Clinical Pharmacy, 38, 310-320.

Vandael, E., Vandenberk, B., Vandenberghe, J., Willems & R., Foulon, V. (2017). Risk factors for QTc-prolongation: systematic review of the evidence. International Journal of Clinical Pharmacy, 39, 16-25.

van der Sijs, H., Kowlesar, R., Klootwijk, A.P., Nelwan, S.P., Vulto, A.G. & van Gelder, T. (2009). Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. British Journal of Clinical Pharmacology, 67, 347-54.

van Merriënboer, J.J.G. & Kirschner, P.A. (2012). Ten Steps to Complex Learning: A Systematic Approach to Four-Component Instructional Design. New York, Routledge.

van Noord, C., Eijgelsheim, M. & Stricker, B.H. (2010). Drug- and non-drug-associated QT interval prolongation. British Journal of Clinical Pharmacology, 70, 16-23.

Warnier, M., Rutten, F., Souverein, P., Hoes, A., de Boer, A., De Bruin, M. (2014). Are ECG Monitoring Recommendations before Prescription of QT Prolonging Drugs Applied in Daily Practice? The Example of Haloperidol. Pharmacoepidemiology Drug Safety, 23, 228-9.


Refbacks

  • There are currently no refbacks.
article/comments.tpl article/footer.tpl